Last updated on November 2017

A Randomized, Double-blind, Placebo-controlled, Multicenter Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder


Brief description of study

A Randomized, Double-blind, Placebo-controlled, Multicenter Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder

Detailed Study Description

The purpose of this research study is to evaluate the efficacy (how well the drug works), safety and tolerability (the side effects) of Rapastinel compared to placebo in subjects with major depressive disorder who are also receiving an approved antidepressant. A placebo is a medically inactive substance that looks like study treatment, but does not contain the active ingredients.

The study drug, Rapastinel or placebo, will be administered intravenously in this study.

Clinical Study Identifier: TX8324

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Karen Godoy

Pacific Clinical Research Medical Group
Upland, CA USA
  Connect »

Alina Goldshtein

SPRI CLINICAL TRIALS BROOKLYN
Brooklyn, NY USA
  Connect »

Mellissa Henry, RN, MSN, NP

Pharmacology Research Institute, Los Alamitos
Los Alamitos, CA USA
  Connect »